ReviewJournal of the American College of Cardiology2016
Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know.
Review in Journal of the American College of Cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes.Journal of the American College of Cardiology · 2025 · on this mapPooled it
- Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis.BMC pharmacology & toxicology · 2018Pooled it
- Pooled it
- Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).American heart journal · 2017Trial
- Beyond glycemic control: clinical cardiovascular effects of tirzepatide-a narrative review.Therapeutic advances in endocrinology and metabolism · 2026Review
- Cardiovascular Events and Heart Failure in Patients With Type 2 Diabetes Treated With Dipeptidyl Peptidase-4 Inhibitors: A Meta-Analysis.Current therapeutic research, clinical and experimental · 2025Review
- Development of Syringaldehyde as an Agonist of the GLP-1 Receptor to Alleviate Diabetic Disorders in Animal Models.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Unveiling the Anti-Cholera and Active Diabetic Renoprotective Compounds of Maqian Essential Oil: A Computational and Molecular Dynamics Study.Molecules (Basel, Switzerland) · 2023Article
- DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits.Military Medical Research · 2022Review
- Renoprotective Effects of DPP-4 Inhibitors.Antioxidants (Basel, Switzerland) · 2021Review
- Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019Article
- Introduction.Journal of managed care & specialty pharmacy · 2018Article
- Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus.Current heart failure reports · 2017Review
- Role of Incretin Axis in Inflammatory Bowel Disease.Frontiers in immunology · 2017Review
- Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies.Current opinion in lipidology · 2016Review
- Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence.International journal of molecular sciences · 2016Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Incretin-based therapies are effective glucose-lowering drugs that have an increasing role in the treatment of type 2 diabetes because of their efficacy, safety, and ease of use. Both glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used for glycemic control as adjuncts to metformin, other oral antiglycemic agents, or insulin. Glucagon-like peptide-1 receptor agonists may have additional effects, such as weight loss, that may be advantageous in obese patients. There is a large body of evidence from randomized controlled clinical trials supporting the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and some glucagon-like peptide-1 receptor agonists, at least in the short term. However, concerns have been raised, particularly regarding their safety in patients with heart failure. In this review, the authors provide a brief but practical evidence-based analysis of the use of incretin-based agents in patients with diabetes, their efficacy, and cardiovascular safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.